Important pro-pharmacy, pro-patient, and pro-taxpayer legislative measures are advancing through regular order in both the House and Senate with overwhelming bipartisan support. Congress must swiftly finalize and pass PBM reform legislation that contains the following:

- The **Drug Price Transparency in Medicaid Act** (H.R. 1613/S. 1038), sponsored by Reps. Buddy Carter (R-Ga.) and Vicente Gonzalez (D-Texas) in the House and Sens. Peter Welch (D-Vt.) and Roger Marshall (R-Kan.) in the Senate. It prohibits the use of spread pricing in Medicaid managed care programs and would move to a fair and transparent pharmacy reimbursement system based on average acquisition costs plus the state’s Medicaid fee-for-service dispensing fee. It requires all pharmacies to respond to the National Average Drug Acquisition Costs (NADAC) survey. This legislation also saves taxpayers over $1 billion.  
  - Passed the full House by a vote of 320-71 as part of the **Lower Costs, More Transparency Act** (H.R. 5378)  
  - Included in the **Modernizing and Ensuring PBM Accountability Act** (S. 2973), which passed the Senate Finance Committee 26-1

- The **Neighborhood Options for Patients Buying Medicines (NO PBMs) Act** (H.R. 5400/S. 2436), introduced by Reps. Buddy Carter (R-Ga.) and Debbie Dingell (D-Mich.) in the House and Sens. Joe Manchin (D-W.Va.) and Marsha Blackburn (R-Tenn.) in the Senate. It requires CMS to define and enforce “reasonable and relevant” Medicare Part D contract terms. It also would create a process for pharmacies to report contract violations and give the Centers for Medicare & Medicaid Services tools to oversee and enforce reasonable and relevant contract requirements.  
  - Unanimously passed Senate Finance Committee as part of the **Better Mental Health Care, Lower-Cost Drugs, and Extenders Act** (S. 3430)